Publication Name	World Journal of Neurology
Manuscript ID	14311
Country	United States

Received	2014-09-29 11:29
Peer-Review Started	2014-09-29 21:53
To Make the First Decision	2014-10-14 17:48
Return for Revision	2014-10-21 18:54
Revised	2014-10-22 09:45
Second Decision	2014-12-15 08:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-12-19 17:51
Articles in Press	2014-12-19 17:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-26 19:12
Publish the Manuscript Online	2015-03-31 10:53

ISSN	2218-6212 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Review
Article Title	Targeting remyelination treatment for multiple sclerosis
Manuscript Source	Invited Manuscript
All Author List	Maheen Nadeem, Lindsay Sklover and Jacob A Sloane
Funding Agency and Grant Number
Corresponding Author	Jacob A Sloane, Director, Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Ks212, Boston, MA 02115, United States. jsloane@bidmc.harvard.edu
Key Words	Multiple sclerosis; Myelin; Remyelination; Oligodendrocyte; Repurposing; Treatment
Core Tip	Over the last several years numerous remyelination pathways important to multiple sclerosis (MS) have been identified, including those of LINGO-1, hyaluronan, Notch-1, retinoid X receptor receptor, and wnt/β-catenin. Newer discoveries include the pathways involving Chemokine (C-X-C Motif) ligand 12/C-X-C chemokine receptor type 4 and G protein-coupled receptor 17, and the involvement of Endothelin-1 in the Notch pathway. High-throughput screens have identified multiple antimuscarinic drugs with good remyelination. Also identified by screens, clemastine, with similar antimuscarinic but also antihistamine effects, may be useful in remyelination in MS. Drug repurposing, through screens or more serendipitously, has found that many drugs could enhance remyelination, including benztropine, clemastine, quetiapine, fasudil, olesoxime, and ibudilast, among others.
Publish Date	2015-03-31 10:53
Citation	Nadeem M, Sklover L, Sloane JA. Targeting remyelination treatment for multiple sclerosis. World J Neurol 2015; 5(1): 5-16
URL	http://www.wjgnet.com/2218-6212/full/v5/i1/5.htm
DOI	http://dx.doi.org/10.5316/wjn.v5.i1.5

Manuscript File	14311-Review.doc
Answering Reviewers	14311-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14311-Conflict-of-interest statement.pdf
Copyright License Agreement	14311-Copyright assignment.pdf
Peer-review Report	14311-Peer review(s).pdf
Scientific Misconduct Check	14311-CrossCheck.jpg
Scientific Editor Work List	14311-Scientific editor work list.pdf